A systematic review on chronic oxaliplatin-induced peripheral neuropathy and the relation with oxaliplatin administration

Abstract

O-IPN is still present in a great amount of patients in ≥12 months after termination of therapy. A higher cumulative dose is likely to have an influence on the development of long-term O-IPN. More studies are needed that assess long-term neuropathy and oxaliplatin administration by means of validated neuropathy assessments.

Effect of the SOD mimetic MnL4 on in vitro and in vivo oxaliplatin toxicity: Possible aid in chemotherapy induced neuropathy

“…Oxaliplatin possesses a relative low hematological and gastrointestinal toxicity, but CIN can limit its clinical use [33,34]. Therefore, many efforts have been addressed to find adjuvant strategies to reduce CIN.…”

Effects of natural and synthetic isothiocyanate-based H 2 S-releasers against chemotherapy-induced neuropathic pain: Role of Kv7 potassium channels

“…Paclitaxel-induced neurotoxicity is characterized by numbness, tingling and burning pain (Dougherty et al, 2004); repeated oxaliplatin administrations induce a chronic neurological syndrome that persists between and after treatment (Beijers et al, 2014;Souglakos et al, 2002) negatively influencing patient's quality of life. The pharmacological management of chemotherapy-induced neuropathy remains largely ineffective (Hershman et al, 2014).…”

Impact of Oxaliplatin-Induced Neuropathy in Patients with Colorectal Cancer: A Prospective Evaluation at a Single Institution

“…Oxaliplatin is frequently used for crc management in the adjuvant or metastatic setting, and peripheral neuropathy is a dose-limiting effect of that treatment that can persist after cessation of therapy 2 . Previous studies have reported incidences up to 50% for grade 2 or greater neuropathy, and up to 20% for grade 3 or greater neuropathy, but patients with medical conditions or concomitant use of medications that could influence the severity of neuropathy have generally been excluded [3][4][5][6] .…”